M
KRBP

Murchinson’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

Murchinson’s Portfolio KRBP Stock Details KRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-3,333
Closed -$481K – 135
2021
Q2 		$481K Buy
+3,333
New +$836K 0.17% 55

Other funds holding KRBP

KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $339M AUM 120.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $401M AUM 14.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Murchinson's KRBP Position: Q3 2021 in Review

Murchinson sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q3 2021, closing a stake of 3,333 shares — an estimated $481K sold.

Murchinson first reported a position in KRBP in Q2 2021 and held it in 1 quarter. The position peaked at $481K in Q2 2021. 23 funds tracked by Wall St. Rank hold KRBP as of Q3 2021.

  • Murchinson reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Murchinson sold 3,333 Kiromic BioPharma, Inc. Common Stock shares in Q3 2021, an estimated $481K.
  • Murchinson first reported a position in Kiromic BioPharma, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Murchinson's Kiromic BioPharma, Inc. Common Stock position peaked at $481K in Q2 2021.
  • 23 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q3 2021.

Based on Murchinson's 13F filing for Q3 2021, filed 15 Nov 2021.